Shubham Gupta

Director

Nephrology medicine manufacturing plays a critical role in modern healthcare, addressing the growing burden of kidney-related disorders such as chronic kidney disease, dialysis dependency, and associated complications.

In India, where lifestyle diseases and aging populations are increasing the incidence of renal ailments, the demand for specialized nephrology drugs has risen significantly. Traditionally dominated by multinational pharmaceutical companies, this niche segment is now witnessing a transformation driven by domestic manufacturers, contract manufacturing models, and innovation-focused startups.

Set up by one of the youngest entrepreneurs, today Faetza Lifesciences is one such brand which is leveraging this shift to build a strong foothold in the nephrology segment while redefining quality, accessibility, and patient-centric innovation.

The Changing Landscape

The nephrology medicine manufacturing ecosystem in India has evolved considerably over the past decade. Earlier, the market was limited, with only a handful of manufacturers, and there was a common perception that manufacturers primarily focused on promoting their own products.

Due to limited infrastructure and expertise, multinational pharmaceutical companies largely dominated the segment. However, initiatives like “Make in India” have significantly altered this landscape. Domestic manufacturing capabilities have improved, encouraging companies to produce drugs locally rather than rely on imports.

At the same time, the rise of startups and entrepreneurial ventures has increased reliance on third-party manufacturing. With limited resources, these new entrants prefer outsourcing production, leading to a surge in demand for contract manufacturing services.

Today, the nephrology segment is characterized by accessibility, flexibility, and growing independence among pharma companies. Contract manufacturers have become essential partners, enabling businesses to scale operations, maintain efficiency, and focus on marketing and innovation rather than production infrastructure.

Addressing Evolving Patient and Market Needs

In the current nephrology market, demand is increasingly driven by innovation and patient-centric solutions. While there are limited new salts or breakthrough molecules in this segment, there is a strong need to improve existing therapies in terms of usability, compliance, and effectiveness.

Patients undergoing dialysis, for instance, face strict fluid intake restrictions while being required to consume multiple medications daily. This creates a unique challenge in drug administration. Faetza Lifesciences has strategically positioned itself to address such unmet needs by focusing on innovative formulations.

The company has introduced double-strength API formulations, enabling patients to reduce the number of tablets consumed daily. This not only improves compliance but also enhances convenience for patients with restricted water intake.

Additionally, Faetza Lifesciences is exploring advanced drug delivery systems such as tablet-in-tablet technology. This innovation helps mask unpleasant taste and odor, making medications easier to consume, especially for long-term patients. By aligning its product strategy with patient needs, the company is bridging critical gaps in the nephrology segment while catering to evolving client expectations.

Core Competencies in End-to-End Contract Manufacturing

Operating in the nephrology space involves complex challenges, particularly in managing multiple contract manufacturers, varying production timelines, and regulatory requirements. Different drugs often require different manufacturing partners, each with distinct operational standards and lead times ranging from 60 to 90 days or more.

Faetza Lifesciences has developed strong competencies in navigating these complexities. The company maintains a robust network of manufacturers and ensures strict adherence to API regulations and compliance standards.

One of its key strengths lies in maintaining backup manufacturers for each product, ensuring uninterrupted supply and timely delivery to clients. This strategic approach not only mitigates risks associated with dependency on a single manufacturer but also enhances operational flexibility. By combining regulatory awareness with supply chain resilience.

Commitment to Quality, Innovation, and Inclusive Growth

Quality assurance remains a cornerstone of Faetza Lifesciences’ operations. The company adopts stringent quality control measures, including batch-wise certification, random sampling, and third-party laboratory testing. Any batch that does not meet the required standards is rejected outright, reflecting the company’s uncompromising stance on quality.

Furthermore, Faetza Lifesciences emphasizes the use of high-grade APIs and is willing to invest more in superior raw materials rather than compromise on product standards. By ensuring compliance with Good Manufacturing Practices (GMP) and maintaining transparency across processes, the company builds trust with both clients and end-users.

Another distinguishing factor is its inclusive approach to market targeting. Faetza Lifesciences aims to cater to patients across different economic segments, from high-income groups to underserved populations. By balancing pricing with quality, the company ensures broader accessibility to essential nephrology medicines.

Growth Journey and Future Vision

Faetza Lifesciences’ journey reflects resilience, strategic expansion, and a strong entrepreneurial vision. Starting from a small-scale operation in Faridabad, the company gradually built its presence through direct engagement with doctors and healthcare professionals. Expansion into regions like Gurgaon, Noida, Ghaziabad, Delhi and Lucknow marked significant milestones, supported by team growth and persistent efforts to establish credibility in a competitive market.

Looking ahead, the company envisions expanding beyond nephrology into other therapeutic segments such as cardiology, gastroenterology, and neurology. With a strong focus on research, technological adoption, and continuous learning, Faetza Lifesciences aims to stay ahead of industry trends.

Over the next five to ten years, the company aspires to strengthen its client base by offering transparent, end-to-end services while fostering long-term partnerships. By combining innovation, quality, and a patient-first approach, Faetza Lifesciences is well-positioned to emerge as a significant player in India’s evolving pharmaceutical landscape.